NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings

Core Insights - NewAmsterdam Pharma is presenting new clinical data on obicetrapib, a novel oral low-dose therapy for hypercholesterolemia, at upcoming scientific sessions in Europe and the U.S. [1][5] - The company is on track to report topline data from its Phase 3 BROOKLYN trial in HeFH in Q3 2024 and the BROADWAY trial in ASCVD in Q4 2024 [1] Clinical Trials and Presentations - NewAmsterdam will present findings from the OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, showcasing obicetrapib's effects on lipid and lipoprotein biomarkers [1] - The EAS 92nd Congress will feature multiple presentations on obicetrapib, including its impact on HDL and Lp(a) levels, as well as its effects in combination with ezetimibe [2][3] - The NLA 2024 Scientific Sessions will also highlight obicetrapib's significant reductions in Lp(a) and its synergistic effects with ezetimibe [3][4] Product Development - Obicetrapib is being developed as a CETP inhibitor to address the limitations of current LDL-lowering treatments, with Phase 3 trials BROADWAY and BROOKLYN evaluating its efficacy as a monotherapy and in combination with other therapies [5][6] - The company has completed enrollment for the BROOKLYN and BROADWAY trials and is also conducting the PREVAIL trial to assess cardiovascular outcomes [5]